India’s Adult Vaccine Market: Bridging the 84% Gap in Adult Immunization Coverage to Build a Healthier Future

With a rapidly aging population, increasing prevalence of chronic diseases, and growing vulnerability to infectious diseases, the need for adult vaccination in India has never been more urgent. Yet, despite these compelling factors, adult immunization continues to lag, especially in low- and middle-income regions. According to Makreo Research, only 16% of individuals over the age of 50 in India have received any form of vaccination, signaling a significant gap in awareness and prioritization of adult immunization. This blog explores why adult vaccination is critical for India’s health future, the barriers preventing its widespread adoption, and the steps necessary to build a healthier and more resilient population.

Key Drivers of the Global Vaccine Market in 2022 (Excluding COVID-19)

In the global vaccine market, excluding COVID-19 vaccines, 3 key products drove ~50% of the market's value in 2022: the pneumococcal conjugate vaccine (PCV), the seasonal influenza vaccine, and the human papillomavirus (HPV) vaccine. This period also witnessed a significant surge in the shingles and HPV vaccine markets, primarily due to increased volumes. Specifically, shingles vaccine volumes in the USA rose by about 30%, while HPV vaccine volumes in China increased by approximately 25%.

Get a free sample of this report: India Adult Vaccine Market Report

The Growing Need for Adult Vaccination in India

Immunization is widely recognized as one of the most cost-effective healthcare measures, reducing morbidity and mortality from vaccine-preventable diseases (VPDs). While childhood vaccination programs have been highly successful worldwide, adult immunization remains largely untapped, especially in India, which is home to the second-largest population globally. India's population is rapidly aging, with projections indicating that by 2050, one out of every five individuals will be over the age of 50. This demographic shift, coupled with the growing prevalence of comorbidities, immunosenescence (the natural decline in immune system function with age), and a higher susceptibility to VPDs, underscores the urgent need for adult vaccination.

• Neglect of Adult Vaccinations: The adult population frequently overlooks the necessity of vaccinations, particularly when the perceived risk of infection is low, often treating them as optional. In India, many adults, especially the elderly, may have either lost their immunity over time or never received vaccinations. Vaccination in adults typically occurs only when required by travel regulations or specific health conditions.

• Recommended Vaccines and Guidelines: There are approximately 85 FDA-approved vaccines targeting 29 diseases. The CDC recommends adult vaccinations for 15 diseases, including influenza, diphtheria, tetanus, pertussis, varicella, HPV, zoster, mumps, measles, rubella, pneumococcal disease, meningococcal disease, hepatitis A and B, and Haemophilus influenza B. The Expert Group of the Association of Physicians of India on Adult Immunization has recommended a similar schedule, with the addition of a vaccine against typhoid. Most of these vaccines are not universally recommended for adults but are instead based on age and specific criteria.

At least 2/3rd of Indian adults are unaware of adult vaccination, with many still believing that vaccines
are solely for children.

Barriers to Adult Vaccination in India

Despite the evident need, several barriers hinder the adoption of adult vaccination programs in India:

• Lack of National Guidelines: Currently, India lacks well-defined national guidelines for adult vaccination, making it challenging to identify which individuals should be vaccinated based on age or underlying medical conditions. This lack of structure impedes the development of a clear strategy for vaccination rollouts across the country.

• Vaccine Hesitancy: Vaccine hesitancy, particularly in rural areas, remains a significant challenge. Misconceptions, fears about vaccine safety, and a general lack of awareness about the benefits of adult vaccination contribute to this reluctance. In many cases, individuals do not perceive adult immunization as necessary, which can delay or prevent vaccination efforts.

• Cost and Accessibility: The cost of vaccines is another major barrier to widespread adoption. Vaccines can be expensive, and in many cases, are not included in public healthcare programs. This makes them inaccessible for low-income populations, further exacerbating health disparities.

• Inadequate Healthcare Infrastructure: India’s healthcare infrastructure, particularly in rural areas, faces significant challenges. Inadequate surveillance systems, limited access to healthcare providers, and missed opportunities during routine check-ups mean that adult vaccination often falls by the wayside.

• Knowledge Gaps: Both healthcare providers (HCPs) and the public suffer from a lack of knowledge about the importance of adult vaccination. While childhood immunization is widely recognized, adult immunization is not given the same attention or urgency.

Key Age Demographics and Regional Variations

India’s demographic structure plays a crucial role in shaping vaccine strategies. Approximately 68% of India’s population is between the ages of 15 and 64, with around 26% in the 10-24 age group, making India one of the youngest countries globally. However, with an aging population, especially in states like Kerala and Tamil Nadu, there is an increasing need for adult vaccination programs.

• Urban vs. Rural Demographics: Urban areas tend to have younger, more mobile populations, but rural areas, which have higher proportions of children and elderly individuals, face greater challenges in healthcare access. These demographic differences necessitate state-specific vaccination programs that cater to regional needs.

Current Guidelines and Vaccines for Adults

In India, vaccination guidelines for adults vary by region, with the World Health Organization (WHO), the Advisory Committee on Immunization Practices (ACIP) from the Centers for Disease Control and Prevention (CDC), and the Association of Physicians of India (API) offering different recommendations. Some of the vaccines currently recommended for adults in India include:

• MMR (Measles, Mumps, and Rubella)
• DPT (Diphtheria, Pertussis, Tetanus)
• Human Papillomavirus (HPV) Vaccine (9-26 years)
• Pneumococcal Vaccine (For those over 65)
• Zoster Vaccine (For those over 60)
• Influenza Vaccine (For those over 50)

High-risk individuals are also encouraged to take vaccines such as hepatitis, meningococcal, and rabies. Annual influenza vaccinations are particularly recommended for individuals aged 31-50, especially those with chronic illnesses or compromised immune systems.

Top Companies Leading the Way in Adult Vaccination

The adult vaccine market in India is beginning to see some movement, with several key players making strides in improving access to adult immunization. Notable companies in the adult vaccine market include:

• Pfizer India: Pfizer has been actively involved in adult vaccination, particularly for pneumococcal disease, influenza, and HPV, through collaborations with hospitals like Apollo and state governments.

• GlaxoSmithKline (GSK): GSK focuses on preventative healthcare, offering vaccines for a range of diseases, including HPV and shingles, and collaborating with the Indian government to promote pneumococcal vaccines.

• Serum Institute of India (SII): Serum Institute, through partnerships with AstraZeneca and Novavax, has played a significant role in the production of vaccines like Covishield and Covovax, targeting both children and adults.

• Bharat Biotech: Bharat Biotech is another major player, having developed Covaxin for COVID-19 and actively researching vaccines for adult-targeted diseases like influenza and pneumonia.

India's Cervical Cancer Challenge and the Promise of the Cervavac Vaccine

• Cervical cancer, a nearly preventable disease, claims the life of one woman in India every seven minutes, accounting for 21% of global cervical cancer deaths. It is the second most common cancer among Indian women, with 125,000 new diagnoses and over 75,000 deaths annually. The high cost of vaccines, up to INR 4,000 per dose, has made prevention inaccessible for many in low- and middle-income countries, including India.

• In September 2022, the Serum Institute of India launched Cervavac, the country's first indigenously developed quadrivalent HPV vaccine. Priced at INR 2,000 per dose half the cost of its competitors, Gardasil and Cervarix—Cervavac aims to make cervical cancer prevention more accessible. The institute plans to produce 200 million doses, potentially revolutionizing cervical cancer prevention in India and similar regions.

Conclusion

In conclusion, adult vaccination is an essential yet underutilized health strategy in India, particularly as the country faces a rapidly aging population and the growing burden of vaccine-preventable diseases (VPDs). With the right focus and overcoming existing barriers, India has the potential to significantly enhance its adult immunization programs, addressing public health concerns and improving overall health outcomes for its population.

To better understand the dynamics of the Indian adult vaccine market, Makreo Research presents its comprehensive report titled India Adult Vaccine Market Report - Global Vaccination Coverage, Demand, Opportunities, Pipeline Vaccines, and Competitive Analysis. This in-depth study explores key market trends, focusing on the diverse economic, healthcare, and demographic factors influencing vaccine demand across India. The report delves into the market’s historical and current performance, highlighting vaccine demand by disease categories and the evolving needs of different population segments.

Moreover, the report offers insights into the impact of technological advancements, the role of vaccination programs, and government policies shaping the market's growth. It also assesses the major players in the market, including Merck Group, Pfizer Ltd., Sanofi Pasteur, Serum Institute of India, and Bharat Biotech, providing detailed company profiles, recent innovations, and opportunities for stakeholders.

With a thorough analysis of market segments, income groups, and regional variations, the report provides actionable insights into market growth drivers, investments, and technological innovations. This comprehensive study is a valuable resource for stakeholders looking to navigate the opportunities within India’s adult vaccine market and contribute to strengthening its public health infrastructure.

Looking for tailored insights to navigate the India Adult Vaccine Market or the Healthcare Industry? Our Custom Research Services provide the specific data and analysis you need to make informed decisions.

Contact Us:

sales@makreo.com

https://www.makreo.com/contact